These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 7793300

  • 1. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J, Creus M, Fábregues F, Carmona F, Casamitjana R, Peñarrubia J, Rivera F, Vanrell JA.
    Gynecol Endocrinol; 1995 Mar; 9(1):51-8. PubMed ID: 7793300
    [Abstract] [Full Text] [Related]

  • 2. Hormonal and histological evaluation of the luteal phase after combined GnRH-agonist/gonadotrophin treatment for superovulation and luteal phase support in in-vitro fertilization.
    Balasch J, Jové I, Márquez M, Vanrell JA.
    Hum Reprod; 1991 Aug; 6(7):914-7. PubMed ID: 1761657
    [Abstract] [Full Text] [Related]

  • 3. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 4. Human chorionic gonadotropin combined with progesterone for luteal support improves pregnancy rate in patients with low late-midluteal estradiol levels in IVF cycles.
    Fujimoto A, Osuga Y, Fujiwara T, Yano T, Tsutsumi O, Momoeda M, Kugu K, Koga K, Morita Y, Wada O, Taketani Y.
    J Assist Reprod Genet; 2002 Dec; 19(12):550-4. PubMed ID: 12503886
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 6. Incomplete androgen and progesterone suppression following midluteal GnRHa prior to controlled ovarian hyperstimulation for IVF-ET.
    Gelety TJ, Surrey ES.
    J Assist Reprod Genet; 1997 Oct 01; 14(9):525-30. PubMed ID: 9401871
    [Abstract] [Full Text] [Related]

  • 7. [Hormone profile and follicle development in ovarian stimulation treatment for in vitro fertilization. II. Prolactin, estradiol and progesterone profile].
    Sudik R, Fliess FR, Kunkel S.
    Zentralbl Gynakol; 1989 Oct 01; 111(9):567-80. PubMed ID: 2500795
    [Abstract] [Full Text] [Related]

  • 8. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization.
    Urbancsek J, Witthaus E.
    Fertil Steril; 1996 May 01; 65(5):966-71. PubMed ID: 8612858
    [Abstract] [Full Text] [Related]

  • 9. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
    Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S.
    Fertil Steril; 1994 Jul 01; 62(1):35-41. PubMed ID: 8005301
    [Abstract] [Full Text] [Related]

  • 10. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM, Orvieto R, Pinkas H, Sapir-Rufas O, Feldberg D, Fisch B.
    Gynecol Endocrinol; 2004 Nov 01; 19(5):247-52. PubMed ID: 15726912
    [Abstract] [Full Text] [Related]

  • 11. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM, Royburt M, Sabah G, Zukerman Z, Pinkas H, Amit S, Ovadia J, Fisch B.
    J Assist Reprod Genet; 1996 May 01; 13(5):395-400. PubMed ID: 8739055
    [Abstract] [Full Text] [Related]

  • 12. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles.
    Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D.
    Fertil Steril; 2000 Apr 01; 73(4):761-6. PubMed ID: 10731538
    [Abstract] [Full Text] [Related]

  • 13. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
    Mochtar MH, Hogerzeil HV, Mol BW.
    Hum Reprod; 1996 Aug 01; 11(8):1602-5. PubMed ID: 8921100
    [Abstract] [Full Text] [Related]

  • 14. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P, Domingo M, Leader A.
    Hum Reprod; 1992 Apr 01; 7(4):487-9. PubMed ID: 1522190
    [Abstract] [Full Text] [Related]

  • 15. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct 01; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 16. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG, Bourgain C, Kolibianakis E, Tournaye H, Devroey P.
    Hum Reprod; 2005 Jun 01; 20(6):1541-7. PubMed ID: 15705618
    [Abstract] [Full Text] [Related]

  • 17. [Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins].
    Ellenbogen A, David H, Libal Y, Ballas S.
    Harefuah; 1995 Dec 01; 129(11):455-6, 536. PubMed ID: 8846950
    [Abstract] [Full Text] [Related]

  • 18. The early luteal hormonal profile in IVF patients triggered with hCG.
    Vuong LN, Ho TM, Pham TD, Ho VNA, Andersen CY, Humaidan P.
    Hum Reprod; 2020 Jan 01; 35(1):157-166. PubMed ID: 31967304
    [Abstract] [Full Text] [Related]

  • 19. Comparison of androgen levels in conception vs. non-conception cycles following controlled ovarian stimulation using the luteal phase gonadotropin-releasing hormone agonist protocol.
    Check JH, Nazari A, Dietterich C.
    Gynecol Endocrinol; 1995 Sep 01; 9(3):209-14. PubMed ID: 8540290
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.